GUIDA, TERESA
 Distribuzione geografica
Continente #
NA - Nord America 182
EU - Europa 79
AS - Asia 52
AF - Africa 8
Totale 321
Nazione #
US - Stati Uniti d'America 174
SG - Singapore 31
IT - Italia 25
UA - Ucraina 20
CN - Cina 14
FI - Finlandia 12
CA - Canada 8
CI - Costa d'Avorio 8
DE - Germania 6
IN - India 6
NL - Olanda 4
GB - Regno Unito 3
SE - Svezia 3
FR - Francia 2
IE - Irlanda 2
JP - Giappone 1
LU - Lussemburgo 1
RO - Romania 1
Totale 321
Città #
Chandler 30
Singapore 22
Jacksonville 20
Santa Clara 15
Millbury 10
Princeton 8
Ashburn 7
Ottawa 6
New York 5
Amsterdam 4
Augusta 4
Beijing 4
Helsinki 4
Nanchang 4
Napoli 4
Wilmington 4
Woodbridge 4
Boston 3
San Mateo 3
Cantù 2
Des Moines 2
Nanjing 2
Puducherry 2
Pune 2
Toronto 2
Bacoli 1
Bucharest 1
Caserta 1
Changsha 1
Hebei 1
Herndon 1
Leawood 1
Los Angeles 1
Marano Di Napoli 1
Munich 1
Naples 1
Palma Campania 1
Pozzuoli 1
Sannomaru 1
Seattle 1
Shanghai 1
Shenyang 1
Trento 1
Turin 1
Udine 1
Villabate 1
Walnut 1
Yellow Springs 1
Totale 196
Nome #
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer 56
BAY 43-9006 inhibition of oncogenic RET mutants 53
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes 50
NCOA4 inhibits initiation of DNA replication to maintain genome stability 49
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 41
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas 38
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. 28
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. 17
Totale 332
Categoria #
all - tutte 1.401
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.401


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202024 0 0 0 0 4 1 1 0 0 6 5 7
2020/202144 0 4 4 4 4 4 4 0 4 0 15 1
2021/202240 1 0 0 1 0 4 0 1 2 3 12 16
2022/202366 8 5 2 4 12 7 0 8 10 4 3 3
2023/202452 1 8 2 7 1 6 4 8 0 2 10 3
2024/202549 12 18 5 3 11 0 0 0 0 0 0 0
Totale 332